Welcome to our dedicated page for Bioatla SEC filings (Ticker: BCAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real cost of BioAtla’s CAB antibody trials or the timing of its Beijing manufacturing agreements can take hours in dense SEC disclosures. BioAtla insider trading Form 4 transactions, complicated R&D footnotes, and patent-portfolio risks are scattered across multiple forms, leaving biotech investors piecing together critical data.
Stock Titan solves that problem. Our AI-powered summaries turn a 300-page BioAtla annual report 10-K simplified into key takeaways on cash burn, milestone payments, and CAB pipeline progress. Need the latest BioAtla quarterly earnings report 10-Q filing? We post it in real time and pair it with plain-English financial trendlines. Flash 8-K material events explained—such as interim efficacy results—arrive with context in minutes. And if you want to monitor BioAtla Form 4 insider transactions real-time, instant alerts show every executive stock move alongside historical patterns.
- understanding BioAtla SEC documents with AI—no biotech PhD required
- BioAtla executive stock transactions Form 4 and ownership shifts at a glance
- BioAtla proxy statement executive compensation decoded for dilution impact
- BioAtla earnings report filing analysis highlighting clinical spend versus cash runway
Whether you are screening for catalytic trial milestones, assessing patent strengths, or comparing quarter-on-quarter burn rates, our comprehensive dashboard has every filing type. Investors routinely ask, “How do I track BioAtla insider activity before data readouts?� or “Where can I see BioAtla SEC filings explained simply?”—the answer is right here. Stay ahead with AI context, real-time alerts, and a single view of every disclosure you need to make informed decisions on this innovative oncology company.
BioAtla, Inc. (Nasdaq: BCAB) filed a Form 8-K covering two routine corporate matters: approval of its 2025 Corporate Bonus Plan and the final results of its 2025 Annual Meeting of Stockholders.
2025 Corporate Bonus Plan (Item 5.02): On 17 June 2025 the Board’s Compensation Committee adopted a cash-based incentive plan for the Chief Executive Officer, Chief Financial Officer and Chief Medical Officer. Payouts are driven by four weighted corporate performance goals—clinical development milestones (25%), financing objectives (50%), financial & people objectives (20%), and brand awareness (5%). A minimum threshold of 50 % aggregate achievement is required for any payout; actual bonuses may range from 50 % to 125 % of the executive’s target opportunity. Target bonuses are set as a percentage of base salary: 60 % for CEO Jay Short and 40 % for both CFO Richard Waldron and CMO Eric Sievers.
Annual Meeting results (Item 5.07): Held virtually on 18 June 2025, the meeting reached a quorum with 30,358,471 shares (�52 % of shares outstanding) represented. Shareholders re-elected three Class II directors for three-year terms, with Lawrence Steinman, M.D. receiving the highest support (11.6 million votes for). Ernst & Young LLP was ratified as independent auditor for FY 2025 (30.2 million votes for; 99.5 % support). A non-binding “say-on-pay� resolution passed with 8.96 million votes in favor versus 4.49 million against.
No other material transactions, earnings data, or strategic changes were disclosed in this filing.
BioAtla director Eddie Williams received a significant equity grant on June 18, 2025, consisting of 23,500 restricted stock units (RSUs). The RSUs were granted at $0 cost and will fully vest on the earlier of June 18, 2026, or the next annual stockholder meeting, contingent on Williams' continued service.
Following this transaction, Williams' direct beneficial ownership increased to 60,200 shares. The grant represents a standard director compensation arrangement and was reported in compliance with SEC Section 16(a) requirements.
Key details of the RSU grant:
- Time-based vesting structure with one-year cliff
- No exercise price as these are RSUs, not options
- Direct ownership form
- Filed via power of attorney through Christian Vasquez
BioAtla, Inc. (BCAB) � Form 4 insider transaction
Director Lawrence Steinman reported the grant of 23,500 shares of common stock in the form of time-based restricted stock units (RSUs) on 18 June 2025. The RSUs will vest 100% on the earlier of (i) 18 June 2026 or (ii) the next annual meeting of stockholders, conditional upon his continued board service.
- Transaction code: A (award)
- Transaction price: $0 (equity award, not a market purchase)
- Post-transaction direct ownership: 78,459 common shares
No derivative securities were reported. The filing indicates routine board compensation designed to align director incentives with shareholder interests and does not signal any open-market buying or selling by the insider.
Event: On June 18, 2025 BioAtla, Inc. (ticker BCAB) filed a Form 4 disclosing a change in beneficial ownership by director Mary Ann Gray.
Key Details
- Securities granted: 23,500 shares of common stock issued as a time-based restricted stock unit (RSU) award.
- Transaction price: $0, reflecting that the RSU grant was part of equity compensation rather than an open-market purchase.
- Vesting schedule: 100 % of the RSUs will vest on the earlier of (i) June 18, 2026 or (ii) the company’s next annual meeting of stockholders, subject to continued board service.
- Post-transaction holdings: After the grant, Gray’s direct ownership stands at 77,397 shares.
The filing does not report any sales, option exercises, or derivative securities activity beyond this RSU grant. No 10b5-1 trading plan is referenced for the transaction.
Investor context: A single director-level RSU grant of 23.5k shares is routine board compensation and represents roughly 0.06 % of BioAtla’s ~39 million shares outstanding. While it marginally aligns the director’s incentives with shareholders, it is unlikely to have a material impact on valuation, liquidity, or control dynamics.
BioAtla Director Sylvia McBrinn received a grant of 23,500 restricted stock units (RSUs) on June 18, 2025. Following this transaction, McBrinn's total direct beneficial ownership increased to 59,125 shares of common stock.
Key details of the RSU grant:
- The RSUs were granted at $0 exercise price
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Vesting is contingent on continued service through the vesting date
This Form 4 filing indicates standard equity-based compensation for a board member, which aligns the director's interests with shareholders. The transaction was executed pursuant to the company's director compensation program and represents a significant addition to McBrinn's equity stake in BioAtla.
BioAtla Director Scott Andrew Smith received a significant equity grant on June 18, 2025, consisting of 23,500 restricted stock units (RSUs). The RSUs were granted at $0 cost and will fully vest on the earlier of June 18, 2026, or the next annual stockholder meeting, contingent on Smith's continued service.
Following this transaction, Smith's direct beneficial ownership increased to 321,550 shares. This equity award appears to be part of the company's director compensation program, aligning the director's interests with shareholders through a one-year vesting schedule.
- Transaction Type: RSU Grant (Non-derivative securities)
- Reporting Person Role: Director
- Vesting Terms: 100% after one year or next annual meeting
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
What is BioAtla, Inc.'s core business?
How does the CAB technology work?
What types of therapeutic candidates are in BioAtla's pipeline?
Where does BioAtla operate globally?
What role does intellectual property play at BioAtla?
How does BioAtla address on-target toxicity issues?
How does BioAtla differentiate itself from competitors?
What are the key benefits of the company’s clinical-stage approach?
